InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
0
T+90 hit rate
56%
T+90 mean return
-3.0%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by MCDONNELL MICHAEL R, Chief Financial Officer. Director active across 2 companies, notably BIOGEN INC.. Cumulatively, 16 filings have been logged. History available since 1 September 2021. The latest transaction was disclosed on 15 May 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations16 total
2,152 shares0Common Stock, No Par ValueSEC:0001415889-25-013718:0
3,257 shares0Common StockSEC:0001127602-25-004459:0
2,335 shares0Common StockSEC:0001127602-25-003964:0
2,431 shares0Common Stock, No Par ValueSEC:0001415889-24-013816:0
4,568 shares0Common StockSEC:0001127602-24-006214:0
3,257 shares0Common StockSEC:0001127602-24-004799:0
2,335 shares0Common StockSEC:0001127602-24-004305:0
2,682 shares0Common StockSEC:0001127602-23-023825:0
2,262 shares0Common Stock, No Par ValueSEC:0001415889-23-008483:0
2,561 shares0Common StockSEC:0001127602-23-006522:0
3,256 shares0Common StockSEC:0001127602-23-005269:0
2,682 shares0Common StockSEC:0001127602-22-022132:0
3,050 shares0Common Stock, No Par ValueSEC:0001415889-22-005723:0
1,981 shares0Common StockSEC:0001127602-22-006275:0
2,681 shares@ US$338.2450.0% of flowCommon StockSEC:0001127602-21-024863
2,681 shares@ US$338.240.0027% mcap50.0% of flowCommon StockSEC:0001127602-21-024863:0
16 of 16 declarations
About MCDONNELL MICHAEL R
Michael R. McDonnell is the Chief Financial Officer and Executive Vice President of Biogen Inc. and Merit Medical Systems Inc. He is responsible for financial management and strategic financial planning for the companies. With extensive experience in finance, he plays a key role in strategic decision-making and optimizing financial performance. His expertise contributes to the growth and sustainability of companies in the biotechnology and medical device sectors.
